Educational pricing information only — not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a qualified healthcare provider before starting, stopping, or changing any medication, and verify pricing and prescribing requirements with the provider before enrolling.

Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed September 4, 2026·Prices verified September 4, 2026·Methodology v1.0

Regulatory updates: compounded GLP-1

The legal status of compounded semaglutide and tirzepatide has changed more in eighteen months than in the previous decade. This page tracks it, with dates and sources.

Current status

Routine compounding of semaglutide and tirzepatide is no longer lawful on the basis that created the market. The FDA declared both shortages resolved, and enforcement discretion ended for every class of compounder between February 18 and May 22, 2025. Courts upheld the FDA. On April 30, 2026 the agency proposed excluding all three molecules from the 503B bulks list. Claims that compounding achieved "permanent legitimacy" through 503A/503B are false.

The timeline

FDA compounding timeline for semaglutide and tirzepatide — every date sourced to an FDA order or court decision
Date	What happened	Why it matters
March 2022	Semaglutide (Wegovy) added to the FDA drug shortage list.	Shortage begins — the legal window for compounding opens.
August 2022	Ozempic (semaglutide) added to the shortage list.
December 15, 2022	Tirzepatide (Mounjaro, Zepbound) added to the shortage list.	Compounded tirzepatide becomes lawful under the shortage exception.
October 2, 2024	FDA declares the tirzepatide shortage resolved.	The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close.
December 19, 2024	FDA reaffirms the tirzepatide resolution in a declaratory order.	Sets a 60-day (503A) / 90-day (503B) transition.
February 18, 2025	503A enforcement discretion for tirzepatide ENDS.	State-licensed pharmacies must stop compounding tirzepatide copies.
February 21, 2025	FDA removes semaglutide from the shortage list.
March 19, 2025	503B enforcement discretion for tirzepatide ENDS.	Outsourcing facilities must stop compounding tirzepatide copies.
April 22, 2025	503A enforcement discretion for semaglutide ENDS.
April 24, 2025	Court denies the Outsourcing Facilities Association's injunction (semaglutide).	OFA v. FDA, N.D. Tex. — FDA's determination stands.
May 7, 2025	Court upholds FDA on tirzepatide in OFA v. FDA.	The shortage-exception route is closed for both molecules.
May 22, 2025	503B enforcement discretion for semaglutide ENDS.	All shortage-based compounding of both molecules is now outside enforcement discretion.
April 30, 2026	FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.	Finding: no clinical need for outsourcing facilities to compound them from bulk. Comment period closed June 29, 2026.

The rule that governs it

The "essentially a copy" rule

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing drugs that are essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. Once the shortage is resolved, it snaps back.

Why every provider suddenly sells "personalized" and "microdose" doses

With the shortage exception gone, one narrow route remains open to 503A pharmacies: a compounded product is not considered 'essentially a copy' if the prescriber determines, and documents on the prescription, that the change produces a significant clinical difference for that individual patient. This is the legal mechanism — not a clinical breakthrough — behind the sudden, industry-wide appearance of "personalized dosing" and "microdose" GLP-1 programs. Changing the strength so it is not "the same, similar, or easily substitutable" as an approved dose is what keeps the product outside the copy definition.

Patients should understand what that means in practice: the dose you are offered may have been chosen partly to satisfy a regulatory test, not purely a clinical one. FDA's own guidance gives examples of a genuine clinical difference — removing an inactive ingredient because of a documented patient allergy, or switching a tablet to a liquid for a patient who cannot swallow — and expressly notes such changes are not necessarily applicable to GLP-1 drugs. That is a pointed signal about how much weight the agency gives this workaround.

Enforcement and litigation riskEli Lilly and Novo Nordisk are actively litigating against telehealth companies, medical spas and compounding pharmacies marketing compounded copies, and have sent cease-and-desist letters across the sector. Enforcement risk is not theoretical, and it falls on the provider — but a provider that is forced to stop mid-course leaves the patient without continuity of supply.

What is still live

Two things. First, the FDA's 503B bulks-list proposal of April 30, 2026 — which found no clinical need for outsourcing facilities to compound these molecules from bulk — was still in process after its June 29, 2026 comment deadline. If finalised, it closes the 503B route entirely.

Second, litigation continues. Eli Lilly and Novo Nordisk are actively pursuing telehealth companies, medical spas and compounding pharmacies, and have issued cease-and-desist letters across the sector.

This page will ageTreat any page on this topic — including this one — as time-sensitive. This is the fastest-moving area we cover, and a page that was accurate in March may not be accurate in September.

What it means for patients

The risk you carry is not legal exposure — it is continuity of supply. If your pharmacy is forced to stop, your medication stops, potentially mid-titration. Ask any provider what its contingency plan is, and note that the collapse in brand pricing has narrowed the reason to carry that risk at all.

The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of September 4, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.

For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.

Sources

U.S. Food and Drug Administration — Declaratory Order: Resolution of Shortage of Tirzepatide Injection Products (December 19, 2024).
U.S. Food and Drug Administration — Declaratory Order: Resolution of Shortage of Semaglutide Injection Products (February 2025).
U.S. Food and Drug Administration — Guidance on compounded drug products that are essentially copies under section 503A.
U.S. Food and Drug Administration — Proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026).
Outsourcing Facilities Association v. FDA, N.D. Tex. — injunction denied April 24 and May 7, 2025.

Spotted an error? Submit a correction.

SURMOUNT-1 — mean body-weight reduction by tirzepatide dose, 72 weeks

Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.

The numbers behind this page

Three questions to ask before acting on this evidence summary

Every price quoted in this evidence summary comes from the programme's own pricing page and carries the date it was captured.

Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?

A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.

Reading the price against the market

What a longer horizon costs

The figures in this summary sit inside a market with a measurable shape, and that shape is what makes any single price readable.

At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.

Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.

A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.

What a longer horizon costs

The figures in this summary sit inside a market with a measurable shape, and that shape is what makes any single price readable.

Questions this page answers

What is the cheapest verified GLP-1 programme?

NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.

Are compounded GLP-1 medicines FDA-approved?

No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.

Why do the same programmes quote two different prices?

Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.

Where do these prices come from?

Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.